International Journal of Diabetes Mellitus
Volume 1, Issue 1 , Pages 22-25 , April 2009

Approach to dysglycemia: Do we need to treat impaired glucose tolerance and impaired fasting glucose?

References 

  1. International Diabetes Federation, 2006. <www.atlas.idf.org>.
  2. The Ministry of Health, Jordan, Center for Disease Control (CDC) Report, 2004.
  3. Tuomilehto J, Lindstrom J, Eriksson JG, et al. The Finnish diabetes prevention study group: prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350
  4. Knowler WC, Barrett-Conner E, Fowler SE, et al. The diabetes prevention program research group: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403
  5. Vendrame F, Gottlieb PA. Prediabetes: prediction and prevention trials. Endocrinol Metab Clin North Am. 2004;33:75–92
  6. Singleton Robinson, Smith A Gordon, Russell James W, et al. Microvascular complications of impaired glucose tolerance. Diabetes. 2003;52(12):2867–2873
  7. Chiasson JL, Josse RG, Gomis R, et al. The STOPNIDDM trial research group: acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 2002;359:2072–2077
  8. Ramachandran A, Snehalatha C, Mary S, et al. Indian Diabetes Prevention Programme (IDPP): the Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289–297
  9. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in highrisk Hispanic women. Diabetes. 2002;51:2796–2803
  10. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study. Diabetes Care. 1997;20:537–544
  11. Gerstein HC, Yusuf S, Boxch J, et al. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) trial investigators: effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096–1105
  12. Torgerson JS, Hauptman J, Boldrin MN, et al. Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:151–161
  13. Nathan David M, Davidson Mayer B, DeFronzo Ralph A, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. A consensus statement from the American Diabetes Association. Diabetes Care. 2007;30:753–759
  14. Genuth S, Alberti KG, Bennett P, et al. Expert committee on the diagnosis and classification of diabetes mellitus: follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–3167
  15. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Rev. 2002;23:201–229
  16. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National health and nutrition examination survey 1999–2002. Diabetes Care. 2006;29:1263–1268
  17. Ajlouni K, Jaddou H, Batieha A. Diabetes and impaired glucose tolerance in Jordan: prevalence and associated risk factors. J. Intern. Med. 1998;244:317–323
  18. Ajlouni K, Khader YS, Batieha A, et al. An increase in prevalence of diabetes mellitus in Jordan during ten years. J Diabetes Complications. 2008;22:317–324
  19. Nathan David M, Davidson Mayer B, DeFronzo Ralph A, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30(3):753–759
  20. Larson H, Lindgarde F, Berglund G, et al. Prediction of diabetes using ADA or WHO criteria in post-menopausal women: a 10-year follow-up study. Diabetologia. 2004;43:1224–1228
  21. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of ß-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29:1130–1139
  22. Dunstan David W, Zimmet Paul Z, Welborn Timothy A, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian diabetes, obesity and lifestyle study. Diabetes Care. 2002;25:829–834
  23. Franklin GM, Kahn LB, Bender J, et al. Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis valley diabetes study. Am J Epidemiol. 1990;131:633–643
  24. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001;24:1448–1453
  25. Sumner CJ, Sheth S, Griffin JW, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60:108–111
  26. Panzer C, Lauer MS, Brieke A, et al. Association of fasting plasma glucose with heart rate recovery in healthy adults: a population-based study. Diabetes. 2002;51:803–807
  27. Pan XR, Hu YH, Li GW, et al. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and diabetes study. Diabetes Care. 1993;16:150–156
  28. Gabir MM, Hanson RL, Dabelea D, et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care. 2000;23:1113–1118
  29. Tominaga M, Eguchi H, Igarashi K, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata diabetes study. Diabetes Care. 1999;22:920–924
  30. Kuller LH, Velentgas P, Barzilay J, et al. Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol. 2000;20:823–829
  31. Jouven Xavier, Desnos Michel, Guerot Claude, et al. Predicting sudden death in the population. Circulation. 1999;1978–1983
  32. Nielson Christopher, Lange Theodore. Blood glucose and heart failure in nondiabetic patients. Diabetes Care. 2005;28:607–611
  33. Nielson Christopher, Lange Theodore, Hadjokas Nicholas. Blood glucose and coronary artery disease in nondiabetic patients. Diabetes Care. 2006;29:998–1001
  34. Levitan Emily B, Song Yiqing, Ford Earl S, et al. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004;164:2147–2155
  35. Xiang Anny H, Peters Ruth K, Kjos Siri L, et al. Effect of pioglitazone on pancreatic beta cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabete. 2006;55:517–522
  36. Chiasson Jean-Louis, Josse Robert G, Gomis Ramon, et al. STOP – NIDDM trial research group: acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial. Lancet. 2002;359:2072–2077
  37. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomized clinical trials. Diabetes Metab. 2004;30:487–496

PII: S1877-5934(09)00005-8

doi: 10.1016/j.ijdm.2009.03.011

International Journal of Diabetes Mellitus
Volume 1, Issue 1 , Pages 22-25 , April 2009

Article Tools